David Peter Kao

David Peter Kao

Auto-generated profile, based on publicly available information

David Peter Kao

University of Colorado School of Medicine, Aurora, CO

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
LSLaura M. Stevens
Laura M. Stevens
BMBobak J. Mortazavi
Bobak J. Mortazavi
RDRahul C. Deo
Rahul C. Deo
LCLesley Curtis
Lesley Curtis
DKDavid P. Kao
David P. Kao
Use of machine learning (ML) in clinical research is growing steadily given the increasing availability of complex clinical data sets. ML presents important advantages in terms of predictive performance and identifying undiscovered subpopulations of patients with specific physiology and prognoses. Despite this popularity, many clinicians and researchers are not yet familiar with evaluating and interpreting ML analyses. Consequently, readers and peer-reviewers alike may either overestimate or underestimate the validity and credibility of an ML-based model. Conversely, ML experts without clinical experience may present details of the analysis that are too granular for a clinical readership to assess. Overwhelming evidence has shown poor reproducibility and reporting of ML models in clinical research suggesting the need for ML analyses to be presented in a clear, concise, and comprehensible manner to facilitate understanding and critical evaluation. We present a recommendation for transparent and structured reporting of ML analysis results specifically directed at clinical researchers. Furthermore, we provide a list of key reporting elements with examples that can be used as a template when preparing and submitting ML-based manuscripts for the same audience.

6 August 2015 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
DKDavid P. Kao
David P. Kao
JLJames D. Lewsey
James D. Lewsey
IAInder S. Anand
Inder S. Anand
BMBarry M. Massie
Barry M. Massie
MZMichael R. Zile
Michael R. Zile
JLJoAnn Lindenfeld
JoAnn Lindenfeld
Background Patients with heart failure and preserved ejection fraction (HFpEF) have a poor prognosis, and no therapies have been proven to improve outcomes. It has been proposed that heart failure, including HFpEF, represents overlapping syndromes that may have different prognoses. We present an exploratory study of patients enrolled in the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I‐PRESERVE) using latent class analysis (LCA) with validation using the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Preserved study to identify HFpEF subgroups. Methods and results In total, 4113 HFpEF patients randomized to irbesartan or placebo were characterized according to 11 clinical features. The HFpEF subgroups were identified using LCA. Event‐free survival and effect of irbesartan on the composite of all‐cause mortality and cardiovascular hospitalization were determined for each subgroup. Subgroup definitions were applied to 3203 patients enrolled in CHARM‐Preserved to validate observations regarding prognosis and treatment response. Six subgroups were identified with significant differences in event‐free survival (P < 0.001). Clinical profiles and prognoses of the six subgroups were similar in CHARM‐Preserved. The two subgroups with the worst event‐free survival in both studies were characterized by a high prevalence of obesity, hyperlipidaemia, diabetes mellitus, anaemia, and renal insufficiency (Subgroup C) and by female predominance, advanced age, lower body mass index, and high rates of atrial fibrillation, valvular disease, renal insufficiency, and anaemia (Subgroup F). Conclusion Using a data‐driven approach, we identified HFpEF subgroups with significantly different prognoses. Further development of this approach for characterizing HFpEF subgroups is warranted.

1 March 2019 in JACC: Heart Failure
Verified
Journal Article
Closed access
MMMiranda Merrill
Miranda Merrill
NSNancy K. Sweitzer
Nancy K. Sweitzer
JLJoAnn Lindenfeld
JoAnn Lindenfeld
DKDavid P. Kao
David P. Kao

17 November 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
LALarry A. Allen
Larry A. Allen
GVGrace Venechuk
Grace Venechuk
CMColleen K. McIlvennan
Colleen K. McIlvennan
RPRobert L. Page
Robert L. Page
CKChristopher E. Knoepke
Christopher E. Knoepke
DMDaniel D. Matlock
Daniel D. Matlock
Background: Major gaps exist in the routine initiation and dose up-titration of guideline-directed medical therapies (GDMT) for patients with heart failure with reduced ejection fraction. Without novel approaches to improve prescribing, the cumulative benefits of heart failure with reduced ejection fraction treatment will be largely unrealized. Direct-to-consumer marketing and shared decision making reflect a culture where patients are increasingly involved in treatment choices, creating opportunities for prescribing interventions that engage patients. Methods: The EPIC-HF (Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction) trial randomized patients with heart failure with reduced ejection fraction from a diverse health system to usual care versus patient activation tools—a 3-minute video and 1-page checklist—delivered electronically 1 week before, 3 days before, and 24 hours before a cardiology clinic visit. The tools encouraged patients to work collaboratively with their clinicians to “make one positive change” in heart failure with reduced ejection fraction prescribing. The primary endpoint was the percentage of patients with GDMT medication initiations and dose intensifications from immediately preceding the cardiology clinic visit to 30 days after, compared with usual care during the same period. Results: EPIC-HF enrolled 306 patients, 290 of whom attended a clinic visit during the study period: 145 were sent the patient activation tools and 145 were controls. The median age of patients was 65 years; 29% were female, 11% were Black, 7% were Hispanic, and the median ejection fraction was 32%. Preclinic data revealed significant GDMT opportunities, with no patients on target doses of β-blocker, sacubitril/valsartan, and mineralocorticoid receptor antagonists. From immediately preceding the cardiology clinic visit to 30 days after, 49.0% in the intervention and 29.7% in the control experienced an initiation or intensification of their GDMT ( P =0.001). The majority of these changes were made at the clinician encounter itself and involved dose uptitrations. There were no deaths and no significant differences in hospitalization or emergency department visits at 30 days between groups. Conclusions: A patient activation tool delivered electronically before a cardiology clinic visit improved clinician intensification of GDMT. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03334188.

1 October 2013 in JACC: Heart Failure
Verified
Journal Article
Closed access
DKDavid P. Kao
David P. Kao
EHEileen Hsich
Eileen Hsich
JLJoAnn Lindenfeld
JoAnn Lindenfeld

1 November 2010 in JACC
Verified
Journal Article
Closed access
GYGeoffrey J. Yoon
Geoffrey J. Yoon
MTMelinda L. Telli
Melinda L. Telli
DKDavid P. Kao
David P. Kao
KMKelly Y. Matsuda
Kelly Y. Matsuda
RCRobert W. Carlson
Robert W. Carlson
RWRonald M. Witteles
Ronald M. Witteles